New combo aims to control CLL in just one year

NCT ID NCT06333262

Recruiting now Disease control Sponsor: Inhye Ahn Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a one-year treatment plan using two drugs, pirtobrutinib and obinutuzumab, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have not had treatment before. The goal is to see if this fixed-duration therapy can control the disease effectively. About 60 participants will receive the combination over 12 cycles.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Brigham & Women's Hospital
RECRUITING

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
New England Cancer Specialists
RECRUITING

Scarborough, Maine, 04074, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.